$14.73 4.8%
RCUS Stock Price vs. AI Score (Last 150 days)
Data gathered: July 18

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Arcus Biosciences

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.

Arcus Biosciences
Price $14.73
Target Price Sign up
Volume 473,030
Market Cap $1.45B
Year Range $13.43 - $20.18
Dividend Yield 0%
Revenue per Employee $647,541
Industry Biotechnology

In the news

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '24145M55M90M-4M-13M-0.050
Q4 '2331M32M-1M-81M-88M-1.080
Q3 '2332M30M2M-71M-79M-0.940
Q2 '2329M28M1M-75M-81M-1.040
Q1 '2325M32M-7M-80M-84M-1.090

Insider Transactions View All

Jarrett Jennifer filed to sell 215,253 shares at $17.6.
March 29 '24
Jarrett Jennifer filed to sell 226,804 shares at $18.6.
March 20 '24
Jarrett Jennifer filed to sell 228,100 shares at $17.8.
March 20 '24
Jaen Juan C. filed to sell 1,188,233 shares at $20.1.
February 28 '24
Jarrett Jennifer filed to sell 240,253 shares at $20.1.
February 28 '24

What is the Market Cap of Arcus Biosciences?

The Market Cap of Arcus Biosciences is $1.45B.

How Many People Work at Arcus Biosciences?

As of our latest update, Arcus Biosciences employed approximately 366 people worldwide. However, it's important to note that Arcus Biosciences' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Arcus Biosciences' revenue per employee?

$647,541. To calculate Arcus Biosciences' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Arcus Biosciences?

Currently, the price of one share of Arcus Biosciences stock is $14.73.

How can I analyze the RCUS stock price chart for investment decisions?

The RCUS stock price chart above provides a comprehensive visual representation of Arcus Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Arcus Biosciences shares. Our platform offers an up-to-date RCUS stock price chart, along with technical data analysis and alternative data insights.

Does RCUS offer dividends to its shareholders?

As of our latest update, Arcus Biosciences (RCUS) does not offer dividends to its shareholders. Investors interested in Arcus Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Arcus Biosciences?

Some of the similar stocks of Arcus Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.